Christopher B. Ehrlich, Director at eFFECTOR Therapeutics, Inc. (EFTR), bought 346 shares at $0.57 ($197) on 2022-10-04, disclosed to the SEC on 2022-10-06.
Open-market purchase of $197 EFTR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| EFTR | BUY | 2022-02-10 | $10K | — | Filing → |
| EFTR | BUY | 2022-02-07 | $31K | — | Filing → |
| EFTR | BUY | 2022-01-31 | $27K | — | Filing → |